2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1495 Targeting ATF4 enhances chemosensitivity to idarubicin and cytarabine in acute myeloid leukemia

Christina D Sotiropoulou, MSc, Eleni Katsantoni2, Christos K Kontos, PhD3, Anthi Bouchla4, Theodora Chatzilygeroudi, MD, PhD5, Sotirios G Papageorgiou, MD, PhD6, Christina Apostolopoulou, MD7, Ioulia Markaki, MD8, Georgia Karamanou, MD9, Theodoros Karantanos, MD, PhD10, Vassiliki Pappa Sr, MD11
1 National and Kapodistrian University of Athens, Athens, Greece
2 Academy of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece, National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece, National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 Johns Hopkins University, Baltimore, United States
11 National and Kapodistrian University of Athens, Athens, Greece, National and Kapodistrian University of Athens, Athens, Greece

Introduction: Acute myeloid leukemia (AML) is often characterized by impaired DNA damage response (DDR), promoting chemoresistance and disease progression. The integrated stress response (ISR) protein PPP1R15A (GADD34) regulates DDR and apoptosis under genotoxic stress. Our group has shown that PPP1R15A is upregulated in AML blasts and linked to chemotherapy resistance. The downstream effectors of the ISR, ATF4 and PPP1R15A, form a regulatory axis that may sustain leukemic cell survival under chemotherapy-induced stress. On this basis, we investigated whether pharmacological inhibition of ATF4 could enhance the cytotoxic efficacy of idarubicin and cytarabine in AML cells.

Methods: ATF4 inhibition studies were performed in MOLM-13 and KASUMI-1 AML cells. Dose-dependent assays were conducted to determine 24-hour IC50 values. Cells were subsequently treated with 0.5×, 1×, and 2× IC50 concentrations of idarubicin, cytarabine, ATF4 inhibitor, and their combinations for 6 and 12 hours. Cell lysates were then subjected to immunoblot analysis to determine ATF4, p-eIF2α, and total eIF2α protein levels. Additionally, transcriptional output was assessed by RT-qPCR for ATF4 target genes, including PPP1R15A, DDIT3, ASNS, and ATF3. Specifically, we measured the relative expression levels using the 2^−ΔΔCt method. To validate the findings, the same treatment protocol and gene expression analyses were applied in CD34+ cells isolated from AML patients and healthy cord blood. Cell proliferation and viability were assessed by CCK-8 assay across all treatment conditions, with parallel RT-qPCR analysis of the ATF4 target genes. All experiments were performed in triplicate. Statistical significance was determined using one-way ANOVA and Student's t-test, with p<0.05 considered statistically significant.

Results: ATF4 targeting significantly reduced AML cell viability, with IC50 values ranging from 45–55 nM in MOLM-13 and KASUMI-1 cells. Pharmacologic inhibition led to a dose-dependent decrease in ATF4 protein levels, while p-eIF2α and total eIF2α remained unchanged. RT-qPCR analysis revealed suppression of canonical ATF4 transcriptional targets, including PPP1R15A, DDIT3, ASNS, and ATF3. Significantly, combination treatment with idarubicin, cytarabine, and the ATF4 inhibitor resulted in a synergistic reduction in AML cell viability compared to either chemotherapeutic agent alone. Specifically, in MOLM-13 cells, viability decreased to 34% with the idarubicin/ATF4 inhibitor combination, compared with 47% and 53% with idarubicin or ATF4 inhibitor alone, respectively, and to 30% with the cytarabine/ATF4 inhibitor combination, compared with 42% and 53% with cytarabine or ATF4 inhibitor alone, respectively. A similar synergistic pattern was observed in KASUMI-1 cells, with viability reduced to 32% and 28% for the idarubicin and cytarabine/ATF4 inhibitor combinations, respectively, versus 45%, 43%, and 58% with idarubicin, cytarabine, or ATF4 inhibitor alone. The suppression of ATF4 target gene expression paralleled the enhanced cytotoxic effect. These findings were validated in primary CD34+ cells isolated from AML patients. Similarly, inhibition of ATF4 decreased the expression of gene targets and potentiated chemotherapy-induced cytotoxicity. In particular, the viability of CD34+ cells was reduced to 27% with the idarubicin/ATF4 inhibitor combination and 22% with the cytarabine/ATF4 inhibitor combination. In parallel, CD34+ cells from healthy cord blood displayed lower sensitivity to the combination treatment, with viability reduced only to 72% and 78%, respectively. All differences described above were statistically significant (p < 0.05).

Conclusions: Our findings show ATF4 is a functionally relevant and druggable node in AML. Pharmacologic inhibition disrupts the ATF4-dependent transcriptional program and synergistically enhances the cytotoxic efficacy of idarubicin and cytarabine. The convergence of these effects in both AML cell lines and primary CD34+ patient samples supports ATF4 inhibition as a promising therapeutic strategy that could improve the efficacy of standard induction chemotherapy in AML. However, the increased sensitivity of AML blasts compared to normal CD34+ cord blood cells to ATF4 inhibition plus cytotoxic chemotherapy needs further confirmation to define the therapeutic window and optimize dosing strategies that maximize efficacy against leukemic blasts while minimizing toxicity to normal hematopoietic progenitors.
Vassiliki Pappa Sr, MD: Climb Bio, Inc. - Research Funding